Investment bank · United States
Wedbush Securities
- Deals
- 19
- M&A
- 10
- Equity raisings
- 9
- Latest
- Sep 2026
Deals
Deals dated after 30 September 2026 are still being collected.
Columns
19 of 19 deals
| Advisers | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 2026 | Aethlon Medical | – | – | Merger | Financial adviser to North Immunology | Announced | – | Biotech | Gibson DunnMaxim GroupProcopio, Cory, Hargreaves & Savitch | North Immunology and Aethlon Medical merger |
| Aug 2026 | Slate Medicines | – | Fulcrum Therapeutics | Merger | Financial adviser to Slate Medicines (target) | Announced | – | Biotech+1 | Cooley (sell-side)Leerink Partners (buy-side)Goodwin (buy-side) | Fulcrum Therapeutics and Slate Medicines merger |
| Aug 2026 | Redx Pharma | – | Skye Bioscience | Acquisition | Financial adviser to Redx Pharma (target) | Announced | – | Biotech+1 | Stifel (buy-side)Morrison & Foerster (buy-side)Cooley (sell-side) | Skye Bioscience acquisition of Redx Pharma |
| Aug 2026 | Cy Biopharma | – | Ensysce Biosciences | Acquisition | Financial adviser to Cy Biopharma (target) | Completed | – | Biotech+1 | Troutman Pepper Locke (buy-side)Orrick (sell-side)Tungsten Advisors (buy-side)H.C. Wainwright & Co. | Ensysce Biosciences acquisition of Cy Biopharma |
| Jul 2026 | Avere Therapeutics | – | – | Placement | Placement agent to the lead managers | Announced | 320.0 | Biotech+1 | Cooley (lead manager)Jefferies (lead manager)Sullivan & CromwellGibson Dunn (issuer) | Avere Therapeutics placement |
| Jul 2026 | Avere Therapeutics | – | NextCure | Merger | Financial adviser to Avere Therapeutics (target) | Announced | – | Biotech+1 | Sullivan & CromwellSidley AustinGibson Dunn (sell-side)Tungsten Advisors (buy-side) | NextCure and Avere Therapeutics merger |
| Jul 2026 | SK hynix | – | – | IPO | Underwriter | Announced | 26,507.1 | Hardware & Semiconductors | BofA Securities (lead manager)Citi (lead manager)Goldman Sachs (lead manager)J.P. Morgan (lead manager)Cantor Fitzgerald (lead manager)Mizuho Securities (lead manager)Needham & Company (lead manager)RBC Capital Markets (lead manager)Rosenblatt Securities (lead manager)Stifel (lead manager)William Blair (lead manager)Nomura (lead manager)WR Securities (lead manager)Cleary Gottlieb Steen & Hamilton (issuer)Paul Hastings (lead manager)Shin & Kim (issuer)Kim & Chang (lead manager) | SK hynix IPO |
| Jun 2026 | Remix Therapeutics | – | Passage Bio | Merger | Financial adviser | Pending | – | Biotech+2 | Latham & Watkins (sell-side)Fenwick & West (buy-side)RBC Capital MarketsCanaccord Genuity | Passage Bio and Remix Therapeutics merger |
| Jun 2026 | Serapha Bio | – | Boundless Bio | Merger | Financial adviser to Serapha Bio (target) | Pending | – | Biotech+1 | Lucid Capital Markets (buy-side)Latham & Watkins (buy-side)Gibson Dunn (sell-side)Goodwin (sell-side) | Boundless Bio and Serapha Bio merger |
| Jun 2026 | Standard BioTools | – | – | Merger | Financial adviser to Treeline Biosciences (target) | Pending | 460.0 | Biotech+2 | Centerview Partners (buy-side)Freshfields (buy-side)Richards, Layton & Finger (buy-side)UBS (buy-side)Fenwick & West (sell-side) | Treeline Biosciences and Standard BioTools merger |
| May 2026 | Mentari Therapeutics | – | InMed Pharmaceuticals | Acquisition | Financial adviser to Mentari Therapeutics (target) | Announced | – | Biotech+1 | Lucid Capital Markets (buy-side)Norton Rose Fulbright (buy-side)Gibson Dunn (sell-side) | InMed Pharmaceuticals acquisition of Mentari Therapeutics |
| May 2026 | Mentari Therapeutics | – | – | Placement | Placement agent to the lead managers | Announced | 290.0 | Biotech+1 | Cooley (lead manager)Gibson Dunn (issuer)Jefferies (lead manager)TD Securities (lead manager)Stifel (lead manager)Guggenheim Securities (lead manager) | Mentari Therapeutics placement |
| May 2026 | Cerebras Systems | – | – | IPO | Underwriter | Listed | 5,550.0 | Hardware & Semiconductors+1 | Morgan Stanley (lead manager)Citi (lead manager)Barclays (lead manager)UBS (lead manager)Mizuho Securities (lead manager)TD Securities (lead manager)Needham & Company (lead manager)Craig-Hallum (lead manager)Rosenblatt Securities (lead manager)Academy Securities (lead manager)MUFG (lead manager)Crédit Agricole CIB (issuer)Latham & Watkins (issuer)Davis Polk (lead manager) | Cerebras Systems IPO |
| May 2026 | Odyssey Therapeutics | – | – | IPO | Underwriter and joint lead manager | Announced | 279.0 | Biotech+1 | J.P. Morgan (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Oppenheimer & Co. (lead manager)Covington & Burling (issuer)Cooley (lead manager) | Odyssey Therapeutics IPO |
| May 2026 | Odyssey Therapeutics | – | – | Placement | Placement agent to the lead managers | Pending | 25.0 | Biotech+1 | J.P. Morgan (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Oppenheimer & Co. (lead manager)Cooley (lead manager) | Odyssey Therapeutics placement |
| Apr 2026 | Hemab Therapeutics Holdings | – | – | IPO | Lead manager | Announced | 301.5 | Biotech+1 | Goldman Sachs (lead manager)Jefferies (lead manager)Evercore (lead manager)WilmerHale (issuer)Goodwin (lead manager) | Hemab Therapeutics Holdings IPO |
| Mar 2026 | Candid Therapeutics | – | Rallybio | Acquisition | Financial adviser to Candid (target) | Pending | – | Biotech+1 | Cooley (sell-side)Evercore (buy-side)Citizens JMP (buy-side)Ropes & Gray (buy-side) | Rallybio acquisition of Candid Therapeutics |
| Jan 2026 | EquipmentShare.com | – | – | IPO | Bookrunner | Listed | 747.3 | Industrial Services+2 | Davis Polk (issuer)Latham & Watkins (lead manager)Holland & Knight (issuer)Goldman Sachs (lead manager)Wells Fargo Securities (lead manager)UBS (lead manager)Citi (lead manager)Guggenheim Securities (lead manager)Citizens JMP (lead manager)Truist Securities (lead manager)Baird (lead manager)Oppenheimer & Co. (lead manager)KeyBanc Capital Markets (lead manager)Fifth Third Securities (lead manager)SMBC Nikko Securities (lead manager)M&T Securities (lead manager)Regions Securities (lead manager)BTIG (lead manager) | EquipmentShare.com IPO |
| Jan 2026 | BitGo Holdings | – | – | IPO | Underwriter | Announced | 212.8 | Crypto & Web3 | Goldman Sachs (lead manager)Citi (lead manager)Deutsche Bank (lead manager)Mizuho Securities (lead manager)Wells Fargo Securities (lead manager)Keefe, Bruyette & Woods (lead manager)Canaccord Genuity (lead manager)Cantor Fitzgerald (lead manager)Clear Street (lead manager)Compass Point Research & Trading (lead manager)Craig-Hallum (lead manager)Rosenblatt Securities (lead manager)SoFi Securities (lead manager)Fenwick & West (issuer)Cravath, Swaine & Moore (lead manager)Whalen LLP (issuer) | BitGo Holdings IPO |
Activity
By announcement date; raisings and IPOs by their own date.
Sector of the business bought or funded.
Disclosed value in US dollars.
Most often across the table
- Tungsten Advisors2 dealsCompare
- Lucid Capital Markets2 dealsCompare
- Troutman Pepper Locke1 dealCompare
- Stifel
1 dealCompare - Morrison & Foerster1 dealCompare
- Leerink Partners1 dealCompare
- Goodwin
1 dealCompare - Evercore
1 dealCompare
Firms advising the other side of the same deals.
Repeat clients
- Avere Therapeutics2 deals
- Mentari Therapeutics2 deals
- Odyssey Therapeutics2 deals